chromobox 3Genealiases: HECH · HP1-GAMMA · HP1Hs-gamma · HP1gamma
Q-omics provides the consensus-scored CBX3 profile across patient tissues and cancer cell-line models. CBX3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CBX3 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, CBX3 protein abundance shows 28,951 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where CBX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX3 survival associations across molecular data types. CBX3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX3 RNA expression–survival associations across cancer types. High CBX3 expression shows unfavorable associations in ACC, MESO, UVM, HNSC, LIHC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CBX3 RNA expression.
This table summarizes CBX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CBX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX3 shows higher tumor expression in HNSC, KIRC, BLCA, LUAD, KIRP and STAD. The HNSC box plot shows higher CBX3 RNA expression in tumor versus normal tissue (log2 FC = +1.461, t-test p < 0.001).
This table shows molecular features associated with CBX3 in patient tissues and cancer cell lines. In patient samples, CBX3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CBX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
